Loading stock data…
SNOA
$1.11+0.02 (+1.83%)
After Hours$1.11+0.00 (+0.00%)· Last close Jun 9
Sonoma Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sonoma Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.11 with a market capitalization of $4M. The stock is currently near its 52-week low of $0.85, remaining 63.4% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 30/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.11
Potential Downside
0%
Whystock Fair Value$1.11
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.20M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.28
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-98.19%
Volume
Today's trading volume
75,257
Recent News
Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Sonoma Pharmaceuticals Soars 95% After Walmart, Amazon Retail Debut
Walmart, Amazon Deal Sends Sonoma Pharmaceuticals Stock Into Frenzy
BC-Most Active Stocks
Nu Holdings Ltd. 57,985,829 12.32
Sonoma Pharmaceuticals (SNOA) Is Attractively Priced Despite Fast-paced Momentum
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
The early winner in the 'Dexit' war for corporate relocations: Nevada
Companies from Andreessen Horowitz to Pershing Square are choosing Nevada as they follow Elon Musk's exit from Delaware.